Department of Radiology & Radiotherapy, Department of Internal & Experimental Medicine 'F Magrassi', Università degli Studi della Campania 'L Vanvitelli', Piazza Miraglia 2, 80138 Naples, Italy.
Department of Medical Oncology, Department of Internal & Experimental Medicine 'F Magrassi', Università degli Studi della Campania 'L Vanvitelli', 80131 Naples, Italy.
Future Oncol. 2018 Dec;14(28):2905-2913. doi: 10.2217/fon-2017-0687. Epub 2018 Feb 13.
Regorafenib induces radiological changes in liver metastasis among patients with metastatic colorectal cancer (mCRC). The standard criteria used to evaluate solid tumor response (Response Evaluation Criteria in Solid Tumors) may be limited in assessing response to biologic agents with anti-angiogenic action.
PATIENTS & METHODS: A total of 67 hepatic lesions in 32 selected patients were analyzed to evaluate tumor attenuation as measured by Hounsfield unit (HU) and size changes.
Following two cycles of regorafenib, tumor HU values decreased in the in 73.1% (49/67) of lesions (average HU changes -25.6%) while tumor size increased in 64.2% (43/67) of them (average size changes +25.4%).
The computed tomography density changes evaluation may be an additional tool, in combination with tumor sizing, to evaluate tumor response in patients treated with regorafenib.
瑞戈非尼可诱导转移性结直肠癌（mCRC）患者肝转移的影像学改变。用于评估实体瘤反应的标准标准（实体瘤反应评估标准）可能在评估具有抗血管生成作用的生物制剂的反应方面存在局限性。
共分析了 32 名患者的 67 个肝病变，以评估通过 Hounsfield 单位（HU）测量的肿瘤衰减和大小变化。
在接受两个周期的瑞戈非尼治疗后，73.1%（49/67）的病变的肿瘤 HU 值降低（平均 HU 变化-25.6%），而其中 64.2%（43/67）的病变肿瘤大小增加（平均大小变化+25.4%）。
与肿瘤大小测量相结合，CT 密度变化评估可能是评估接受瑞戈非尼治疗的患者肿瘤反应的另一种工具。
